Trillions of dollars in market prices alternately have been wiped off and added back to portfolios, leading to high anxiety ...

PLIANT THERAPT (PLRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

CIRCLE PINES, Minn. (AP) — CIRCLE PINES, Minn. (AP) — Northern Technologies International Corp. (NTIC) on Thursday reported earnings of $434,000 in its fiscal second quarter. On a per-share basis, the ...

Skyler Weinand, chief investment officer at Regan Capital, said the Fed is now “stuck” as Trump’s “on and off tariff policy” ...

RICHMOND, Va. (AP) — RICHMOND, Va. (AP) — CarMax Inc. (KMX) on Thursday reported fiscal fourth-quarter net income of $89.9 million. On a per-share basis, the Richmond, Virginia-based company said it ...

Tracey's Top Stock Picks To Keep On Your Watchlist Right Now (31:15) - Episode Roundup: VTR, BRK.B, NFLX, AMN [email protected] Welcome to Episode #441 of the Zacks Market Edge Podcast. Every week, ...

In the latest trading session, IonQ, Inc. (IONQ) closed at $25.89, marking a -1.82% move from the previous day. This change was narrower than the S&P 500's daily loss of 3.46%. Elsewhere, the Dow lost ...

DALTON, Ga. (AP) — DALTON, Ga. (AP) — The Dixie Group Inc. (DXYN) on Thursday reported a loss of $7.2 million in its fourth quarter. On a per-share basis, the Dalton, Georgia-based company said it had ...